{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:47Z","timestamp":1789608107465,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The clinical benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors for preventing and treating cardiovascular events remains controversial. We aimed to study the effect of SGLT2 inhibitors on cardiovascular outcomes and safety events, giving particular attention to the benefits in subgroups of patients with different diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Randomized controlled trials (RCTs) reporting cardiovascular outcomes following the administration of SGLT2 inhibitors and placebo were included in this study. Cardiovascular outcomes included all-cause death, major adverse cardiovascular events (MACEs), cardiovascular (CV) death, myocardial infarction (MI), stroke, and hospitalization for heart failure (HHF). We also focused on the cardiovascular benefits of SGLT2 inhibitor application in subgroups of patients with different diseases, including type 2 diabetes (T2D), heart failure (HF), high risk of atherosclerotic cardiovascular disease (ACD), diagnosed ACD, and chronic kidney disease (CKD). Safety events associated with SGLT2 inhibitors, including acute kidney injury (AKI), diabetic ketoacidosis (DKA), hypoglycemia, urinary tract infection, thromboembolic event, bone fracture, volume depletion, and amputation, were also reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis included 15 RCTs with 78,212 participants. SGLT2 inhibitors reduced the risk of all-cause death (RR 0.89; 95% CI: 0.85\u20130.94; I2 = 32%; <jats:italic>p<\/jats:italic> &amp;lt; 0.01), CV death (RR 0.87; 95% CI: 0.82\u20130.93; I2 = 11%; <jats:italic>p<\/jats:italic> &amp;lt; 0.01), MACEs (RR 0.89; 95% CI: 0.84\u20130.94; I2 = 46%; <jats:italic>p<\/jats:italic> &amp;lt; 0.01), HHF (RR 0.70; 95% CI: 0.66\u20130.74; I2 = 0%; <jats:italic>p<\/jats:italic> &amp;lt; 0.01), and AKI (RR 0.81; 95% CI: 0.73\u20130.90; I2 = 0%; <jats:italic>p<\/jats:italic> &amp;lt; 0.01) but increased the risk of DKA (RR 2.56; 95% CI: 1.72\u20133.80; I2 = 0%; <jats:italic>p<\/jats:italic> &amp;lt; 0.01). However, no apparent benefit in MI and stroke was observed between the SGLT2 inhibitor and control groups. SGLT2 inhibitors reduced the risk of all-cause death, MACEs, CV death, and HHF in diabetic patients; reduced the risk of all-cause death, MACEs, CV death, MI, and HHF in primary prevention; reduced the risk of all-cause death, CV death, and HHF in patients with ACD and HF; and reduced the risk of MACEs, CV death, and HHF in patients with CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SGLT2 inhibitors have a positive effect in reducing the risk of all-cause death, CV death, MACE, HHF, and AKI and increasing the risk of DKA. The application of SGLT2 inhibitors in the primary prevention of ACD also has certain clinical benefits in reducing MI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>[<jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>], identifier [CRD42022306490].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.926979","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T04:34:30Z","timestamp":1665722070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Chen","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Chun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Gang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-kun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/330379a0","article-title":"Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter.","volume":"330","author":"Hediger","year":"1987","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1152\/physiol.00026.2004","article-title":"Surprising versatility of Na+-glucose cotransporters: SLC5.","volume":"19","author":"Wright","year":"2004","journal-title":"Physiology"},{"key":"B4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters.","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia."},{"key":"B6","year":"2008","journal-title":"Guidance for Industry:Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies To Treat Type 2 Diabetes."},{"key":"B7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/nejmoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/nejmoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10741-020-09954-8","article-title":"Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.","volume":"26","author":"Tager","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.tem.2015.05.011","article-title":"SGLT-2 inhibition and glucagon: cause for alarm?","volume":"26","author":"Kibbey","year":"2015","journal-title":"Trends Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis.","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/bmj.320.7237.754","article-title":"Effects of preventive home visits to elderly people living in the community: systematic review.","volume":"320","author":"van Haastregt","year":"2000","journal-title":"Bmj."},{"key":"B18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/nejmoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/nejmoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/nejmoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/nejmoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/nejmoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA."},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/s2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/circulationaha.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease.","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/circulationaha.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial.","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction.","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure.","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/circulationaha.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/nejmoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12881","article-title":"Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.","volume":"19","author":"Al Jobori","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics.","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats.","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: a meta-analysis of randomized clinical trials.","volume":"133","author":"Kumar","year":"2020","journal-title":"Am J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function.","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2020.34.s1.05126","article-title":"Effects of acute SGLT2 blockade and dietary NaCl on glomerular hemodynamics in diabetic rats.","volume":"34","author":"Thomson","year":"2020","journal-title":"FASEB J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/DMSO.S51792","article-title":"Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.","volume":"8","author":"Nitzan","year":"2015","journal-title":"Diabetes Metab Syndr Obes."},{"key":"B48","year":"2015","journal-title":"FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About too much Acid in the Blood and Serious Urinary Tract Infections."},{"key":"B49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.926979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T04:34:35Z","timestamp":1665722075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.926979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2022.926979"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.926979","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"926979"}}